FDA approves J&J, Protagonist's blockbuster-to-be psoriasis pill
Protagonist Therapeutics and Johnson & Johnson have received FDA approval for Icotyde, a once-daily oral pill for moderate-to-severe plaque psoriasis. This approval marks a significant shift from inj...ectable treatments, offering a convenient alternative with high efficacy. Icotyde, the first oral peptide targeting the IL-23 receptor, is expected to achieve rapid market penetration with projected peak sales of $5.5 billion. The drug is also being tested for other immunology indications.
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda ...
Protagonist Therapeutics has opted out of its 50:50 U.S. profit-sharing deal with Takeda for rusfertide, a hepcidin mimetic peptide under FDA review for polycythemia vera. This decision makes Protago...nist eligible for up to $975 million in milestone payments and royalties, enhancing its long-term economic prospects while allowing Takeda exclusive U.S. commercialization rights.
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda ...
Protagonist Therapeutics has opted out of its 50:50 U.S. profit-sharing agreement with Takeda for the drug rusfertide, making it eligible for up to $475 million in opt-out and milestone payments. Thi...s decision allows Takeda exclusive U.S. rights while Protagonist retains potential milestone payments and royalties on global sales.
Protagonist Therapeutics has opted out of its U.S. profit-sharing agreement with Takeda for the drug rusfertide, making it eligible for $200 million upon election and another $200 million upon FDA ap...proval. The opt-out also includes a $75 million milestone payment upon U.S. approval, totaling $475 million. Protagonist remains eligible for up to $975 million in milestones and tiered royalties from worldwide sales.
Takeda and Protagonist Announce U.S. Food and Drug Administration ...
Protagonist Therapeutics and Takeda announced that the FDA has accepted the New Drug Application for rusfertide, granting it Priority Review. Rusfertide, a first-in-class hepcidin mimetic peptide, ta...rgets polycythemia vera, a condition with limited treatment options. This milestone highlights Protagonist's collaboration with Takeda in advancing innovative therapies for hematologic conditions.
Protagonist Reports First Quarter 2026 Financial Results and Provides ...
Protagonist Therapeutics reported its Q1 2026 financial results, highlighting FDA approval of ICOTYDE for plaque psoriasis, triggering a $50 million milestone payment. The company also exercised its ...opt-out right in the Takeda collaboration for rusfertide, receiving a $200 million fee. Protagonist anticipates further milestone payments and royalties from both ICOTYDE and rusfertide, positioning it for future growth.
Protagonist opts for $475M in Takeda payouts instead of splitting US ...
Protagonist Therapeutics has chosen to receive $475 million from Takeda instead of splitting U.S. profits for rusfertide, a drug nearing FDA approval for polycythemia vera. This decision includes $20...0 million now and $275 million upon approval, with potential milestone payments and royalties. CEO Dinesh Patel emphasized the strategic value and partnership with Takeda.
Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
Protagonist Therapeutics plans to opt for a $400 million payment from Takeda instead of sharing U.S. profits for rusfertide, a drug for polycythemia vera. The decision follows the drug's successful p...hase 3 trial and pending FDA approval. Protagonist will also receive milestone payments and royalties on global sales.
